Patients receiving immune checkpoint inhibitors for cancer routinely have their BP checked when they attend for treatment. Could we be repurposing this for hypertension screening? nature.com/articles/s4137… Steve Nicholls Adam Nelson Prof. Eva Segelov Monash Victorian Heart Institute #CardioOncology

Excellent summary of the renal benefits SGLT2 inhibitors by ⁦Carlos G Santos-Gallego, MD⁩ at #ADA2023 ⁦Javed Butler⁩ ⁦Harriette Van Spall, MD MPH 🇨🇦⁩ ⁦Adam Nelson⁩ ⁦Michael Wilkinson⁩ ⁦Mount Sinai Fuster Heart Hospital⁩

Great to have Chris Wong back in town kicking off SAHMRI Heart emerging leaders symposium. Translational data linking dietary factors with propensity for arrhythmia. Uni of Adelaide Adrian Elliott Prash Sanders ChrisBursill

Great to have Steve Greene all the way from Duke Clinical Research Institute here in Adelaide CSANZ reminding us of the importance of simultaneous commencement & rapid titration of HFrEF therapies. Incredible body of work highlighting gaps and importantly a path forward! Carolyn Lam

Happy to inform our “remote follow-up in #PragmaticTrials” at #ACC has #SimPub to Journal of Cardiac Failure. Thanks for the team and mentorship from Adam DeVore, MD, MHS Duke Cardiology Fellows Duke Clinical Research Institute Robert Mentz, MD Gregg Fonarow MD Javed Butler Larry A. Allen, MD Michael Felker Marat Fudim, MD MHS Adam Nelson Adrian “WE NEED RCTS!” Hernandez bit.ly/49uzN3e

REGISTER: thelimbic.com/nephrology/car… A MDT panel presents the latest updates on the use of disease-modifying treatments in cardio-renal metabolic disease and discusses models of care for improved patient outcomes. Brendon Neuen RathikaKrish Adam Nelson A/Prof Sarah Glastras ANZSN

Thanks for the opportunity Steve Nicholls & Carolyn Lam ... Despite housing 60% of the global burden of CVD, our earlier work has shown that < 10% of participants enrolled in seminal cardiometabolic studies are from APAC. Huge opportunities The Asia Pacific Cardiometabolic Consortium jacc.org/doi/abs/10.101…

Fantastic work by Adam Livori - discharge pathways post PCI and CABG look different but use of secondary prevention medications should be similar… plenty of opportunities to improve adoption of evidence based therapies. doi.org/10.1016/j.hlc.…

Thrilled to present the results from the WITHDRAW-AF randomized clinical trial at #ESC2024 - low LVSD relapse rates in recovered AFCM following withdrawal of HF pharmacotherapy Baker Institute University of Melbourne Heart Centre at the Alfred European Society of Cardiology John Mandrola, MD

Loss of kidney function accelerates dramatically after HF, while atherosclerotic & HF risk increases 3-4 fold after CKD progression Highlighting epidemiological & therapeutic synergies between CKD & CV disease Cardio-kidney-metabolic #simpub for #ESCCongress in JACC Journals

Excited to launch The Lancet Commission on Finding Solutions for the Cardiovascular Disease Burden in the Asia Pacific Region with my good friend Carolyn Lam - a lot of work lies ahead with energetic colleagues richard horton Duke-NUS Medical School Monash Victorian Heart Institute

Results of the CAMERA-MRI II study LBCT #ESC2024: catheter ablation in AF and LVSD with LV fibrosis superior to medical therapy with respect to LVEF improvement, functional status, patient symptoms and reverse LA remodeling European Society of Cardiology News John Mandrola, MD peterkistler MBBS PhD FHRS Sandeep Prabhu

#ESCCongress2024 done 👏🏻 👏🏻 Gearing up for Brisbane GPCE ✈️ to talk Lipids & cardiovascular risk with good friend & colleague Adam Nelson Conference link/discount below 👇🏼 Code SPEAKER50ADV to get 50% off your Conference Pass. #GPCEBrisbane invt.io/1txbv5ph0ub

Looking forward to it Dr Rob 🫀🩺 🇦🇺 !!!